Amneal Says Vertical Integration Will Be Key To Compete In Biosimilars
Chirag Patel Says Firm Is Already Proving Itself Against Rivals Such As Pfizer And Amgen
Stressing the need for vertical integration to be a successful biosimilars developer in the long run, Amneal co-CEO Chirag Patel has set out the firm’s future strategy in the area – including aiming to be quicker to market with future launches – as Amneal proves itself against rival biosimilars players in the US market.
